Cutler Group’s Altamira Therapeutics Ltd CYTO Stock Holding History

Cutler Group’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7	Closed	-$3K	–	6364
2021 Q3	$3K	Buy	7 +1	+17%	+$1.13K	﹤0.01%	4911
2021 Q2	$1K	Buy	+6	New	+$8.23K	﹤0.01%	5505
2017 Q1	–	Hold	0	–	-$3K	–	7440
2016 Q4	–	Hold	0	–	–	–	5437
2016 Q3	–	Hold	0	–	–	–	5016

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cutler Group's CYTO Position: Q4 2023 in Review

Cutler Group sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2023, closing a stake of 1 share.

Cutler Group first reported a position in CYTO in Q2 2021 and held it in 10 quarters. The position peaked at $2K in Q1 2022. 4 funds tracked by Wall St. Rank hold CYTO as of Q4 2023.

Cutler Group reported no remaining Altamira Therapeutics Ltd position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 1 Altamira Therapeutics Ltd share in Q4 2023.
Cutler Group first reported a position in Altamira Therapeutics Ltd in Q2 2021 and held it in 10 quarters.
Cutler Group's Altamira Therapeutics Ltd position peaked at $2K in Q1 2022.
4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.